Previous Close | 0.6655 |
Open | 0.6747 |
Bid | 0.6667 x 2900 |
Ask | 0.6900 x 1000 |
Day's Range | 0.6580 - 0.7000 |
52 Week Range | 0.2900 - 2.0800 |
Volume | |
Avg. Volume | 251,063 |
Market Cap | 21.754M |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | -2.7600 |
Earnings Date | Mar 13, 2023 - Mar 17, 2023 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 3.95 |
Sigilon Therapeutics ( NASDAQ:SGTX ) Third Quarter 2022 Results Key Financial Results Revenue: US$4.25m (up 118% from...
Sigilon Therapeutics, Inc. (SGTX) delivered earnings and revenue surprises of 37.21% and 73.55%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Identified important optimization features for its platform to mitigate PFO risks in current and future programs Advanced iPS cell differentiation protocol for the diabetes program in preparation for anticipated IND-enabling studies in 2023 Continued optimization of the MPS-1 program, with plans to initiate IND-enabling studies in the second half of 2023 CAMBRIDGE, Mass., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ: SGTX), a biotechnology company that seeks to develop fu